GlaxoSmithKline GSK
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 73rd percentile, 5-year average 13.9x
#1368 of 2972 stocks by PE (1 = cheapest)
Near the bottom of its 5-year range · 10th percentile, 5-year average 4.7x
#4088 of 5311 stocks by PB (1 = cheapest)
Above its usual level · 64th percentile, 5-year average 2.1x
#2638 of 5150 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 3.95 | – | 4.70 | 10% (cheaper than usual) | #4088 of 5311 (1 = cheapest) |
| PE | 17.31 | 12.68 | 13.88 | 73% (pricier than usual) | #1368 of 2972 (1 = cheapest) |
| PS | 2.21 | 2.12 | 2.06 | 64% (pricier than usual) | #2638 of 5150 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on GSK.
Sign in to join the discussion.